Document Detail


Update on the role of ipilimumab in melanoma and first data on new combination therapies.
MedLine Citation:
PMID:  23299197     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
PURPOSE OF REVIEW: This article provides an update on the therapeutic role of the monoclonal antibody ipilimumab in melanoma. Recent therapeutic combinations, as well as directions for further investigations, will also be discussed. RECENT FINDINGS: By blocking the interaction between CTLA-4 and B7 expressed on activated T lymphocytes and antigen-presenting cells, respectively, ipilimumab inhibits negative signals that physiologically downregulate T-cell activation and exerts its therapeutic activity by upregulating the antitumor activity of T lymphocytes. Ipilimumab has been the first agent to significantly improve the survival of metastatic melanoma patients and to provide long-term benefit to a sizeable proportion of patients treated within phase II/III studies and expanded access programs. On these premises, a number of studies combining ipilimumab with cytotoxic, antiangiogenic, and targeted agents have been most recently conducted. SUMMARY: Ipilimumab is the prototype of a growing family of 'immunomodulating antibodies' and it has demonstrated that immunotherapy will play an increasingly important role in the new treatment approaches for cancer. Combinations of chemotherapy, radiation therapy, and targeted drugs with ipilimumab indicate that additive and synergistic antitumor activity can be achieved. Most importantly, they indicate that involving the immune system is a key strategy to improve the outcome in cancer patients.
Authors:
Michele Maio; Anna M Di Giacomo; Caroline Robert; Alexander M M Eggermont
Related Documents :
12368937 - The importance of histopathological and clinical variables in predicting the evolution ...
16803507 - Clinical and histopathologic factors related to prognosis in primary squamous cell carc...
16500247 - Prognostic index for patients with hepatocellular carcinoma combined with tumor thrombo...
7969707 - Prognostic factors and survival in amyotrophic lateral sclerosis.
2347677 - Prognostic factors in childhood acute lymphoblastic leukaemia.
10189387 - Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leu...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-5
Journal Detail:
Title:  Current opinion in oncology     Volume:  -     ISSN:  1531-703X     ISO Abbreviation:  Curr Opin Oncol     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-9     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9007265     Medline TA:  Curr Opin Oncol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
aMedical Oncology and Immunotherapy, Azienda Ospedaliera Universitaria Senese, Istituto Toscano Tumori, Siena, Italy bMelanoma Unit, INSERM U981, Cancer Institute Gustave Roussy, Villejuif, Paris, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Assessment of genotoxic potential of two mycotoxins in the wing spot test of Drosophila melanogaster...
Next Document:  C-kit-mutated melanomas: the Chinese experience.